Ibio Inc Stock News

Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March  appeared first on Penny Stocks to Buy, Picks, News and Information | P

Check these three biotech penny stocks out for your watchlist The post Top Biotech Penny Stocks to Buy Now? 3 to Watch in March  appeared first on Penny Stocks to Buy, Picks, News and Information | P

Future FinTech Group Inc. (NASDAQ:FTFT) with the stream of -7.70% also noticed, India iBio, Inc. (AMEX:IBIO) encountered a rapid change of -4.17% in the last hour of Tuesdays trading session. The post Sizzler Stock is not to be missed: Future FinTech Group Inc. (NASDAQ:FTFT), iBio, Inc. (AMEX:IBIO) appeared first on Stocks Equity .

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2022 Results - Earnings Call Transcript

iBio press release (IBIO): FQ2 GAAP EPS of -$0.05 misses by $0.01.Revenue of $0.17M (-76.1% Y/Y) misses by $0.08M.Shares -0.85%.As of December 31, 2021, iBio had cash and

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharmi

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update.

iBio (NYSE:IBIO) is scheduled to announce Q2 earnings results on Monday, February 14th, after market close.The consensus EPS Estimate is -$0.04 (flat Y/Y) and the consensus Revenue

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-bas

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

iBio <> provided an update on its lead COVID-19 vaccine program IBIO-202. The company said that according to feedback received from the U.S

iBio Inc (NYSE: IBIO ) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company''s lead COVID-19 vaccine program. In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation … Full story available on Benzinga.com

iBio Inc. (IBIO) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $108M. The stock is currently down 8.9% year-to-date, down 68.4% over the past 12 months, and down 87.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 35.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 424.2% The company's stock price performance over the past 12 months lags the peer average by 102.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

iBio Inc. (IBIO) shares closed today at 0.8% above its 52 week low of $0.51, giving the company a market cap of $114M. The stock is currently down 4.4% year-to-date, down 56.3% over the past 12 months, and down 86.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 40.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 408.7% The company's stock price performance over the past 12 months lags the peer average by 73.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.